Indexed with PubMed and Science Citation Index (E) 
Users online: 1705 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (223 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded108    
    Comments [Add]    

Recommend this journal


 Table of Contents    
Year : 2016  |  Volume : 82  |  Issue : 4  |  Page : 417-418

Immunotherapy or not? The mystery deepens

1 Department of Dermatology, Venereology and Leprosy, MGM Medical College and Hospital, Navi Mumbai, Maharashtra, India
2 Consultant Dermatologist, Dr. Amit Kerure Skin Clinic, Navi Mumbai, Maharashtra, India

Date of Web Publication6-Jun-2016

Correspondence Address:
Dr. Shaurya Rohatgi
Department of Dermatology, Venereology and Leprosy, MGM Medical College and Hospital, Navi Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0378-6323.182970

Rights and Permissions

How to cite this article:
Rohatgi S, Kerure AS, Udare S, Jerajani HR. Immunotherapy or not? The mystery deepens. Indian J Dermatol Venereol Leprol 2016;82:417-8

How to cite this URL:
Rohatgi S, Kerure AS, Udare S, Jerajani HR. Immunotherapy or not? The mystery deepens. Indian J Dermatol Venereol Leprol [serial online] 2016 [cited 2020 Oct 29];82:417-8. Available from:


This is with reference to the study by Saoji et al. on immunotherapy of warts with purified protein derivative (PPD).[1] Although it is a carefully executed study; in our view, the use of the term “immunotherapy” is an inappropriate description for the method employed by the authors. We understand that they achieved good clearance rates using the methods described in the report but injecting PPD into multiple lesions defies the true meaning of immunotherapy.

In the section methods, they write “2.5 tuberculin units (TU) of PPD was injected into each lesion.[1] In case of multiple lesions, a maximum of 10 representative lesions covering all the sites and a maximum of 25 TU of PPD was injected during each session.” Immunotherapy is defined as treatment designed to produce immunity to a disease or enhance the resistance of the immune system to an active disease process. It involves injecting a specific dose of antigen at specific intervals in order to sensitize the immune system. Vaccination is also a type of immunotherapy and all vaccines are administered as a single dose, not as multiple doses throughout the body. Booster doses are given for many vaccines but that is not to be considered as multiple doses. By that principle, immunotherapy for warts should not be given into all or multiple lesions, but only one lesion.

We are not suggesting that injecting tuberculin or any other form of immunotherapy into multiple warts in the same patient is wrong. The authors have shown that it works well but this practice may lead to confusion for clinicians and future researchers attempting this modality of treatment. It may create doubt as to how many warts to inject and how much to inject in each patient. Therefore, the exact and effective dose of the antigen will not be recognized and proper treatment guidelines cannot be formulated. Moreover, it has been shown in multiple studies that immunotherapy works well even if we inject the agent in only one lesion.[2],[3],[4],[5] The authors of this letter have conducted a similar study in which a specific amount of PPD (0.1 ml) was injected in the same target wart with up to 100% results.[5] Therefore, we suggest that following this protocol will maintain uniformity and may avoid confusion for future studies as well as clinical practice.

Immunotherapy is a new treatment modality for warts and many studies are reporting its beneficial effect. However, recent British guidelines state that there is no robust evidence to support the use of intralesional immunotherapy.[6] This recommendation stems from the fact that randomized controlled trials are lacking. Most studies do not have a control group and simply mention cure rates without comparison to either control or another traditional modality of treatment. Nofal and Nofal included saline as control in their comparative study for evaluating the efficacy of intralesional measles, mumps and rubella vaccine[2] Interestingly, complete or partial response was also seen in the saline group (27.5% and 15%, respectively). The response in the saline group could be related to some amount of tissue autoinoculation occurring during intralesional injection. The study protocol dictated injection into the single largest wart for all patients. But if we increase the number of warts to be injected, this would increase the chance of autoinoculation of wart tissue and thereby increase the clearance rates of either group. Therefore, while it may be useful for boosting response rates, this is not true immunotherapy but simply manipulation of the lesion.

There is another important precaution to be taken while administering tuberculin which may have been ignored. The authors mention that history of tuberculosis was not considered as an exclusion criterion. But, according to the tuberculin package insert, PPD should be administered with caution, or not at all, in persons with documented active tuberculosis or documented treatment in the past because of the severity of reactions (e.g., vesiculation, ulceration or necrosis) that may occur at the test site.[7] This may be of additional concern in a country like India where tuberculosis is endemic and frequent. Moreover, if we inject multiple lesions, the chances of a severe local reaction may increase further.

In conclusion, this study does not concretely define the amount of PPD required and the number of lesions to be injected. In addition, there is uncertainty about how to decide the amount of PPD required in relation to the extent of the disease, whether to inject the same dosage in subsequent sittings and what to do if numbers of lesions reduce. More studies are needed to resolve these ambiguities.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Saoji V, Lade NR, Gadegone R, Bhat A. Immunotherapy using purified protein derivative in the treatment of warts: An open uncontrolled trial. Indian J Dermatol Venereol Leprol 2016;82:42-6.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
Nofal A, Nofal E. Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol 2010;24:1166-70.  Back to cited text no. 2
Shaheen MA, Salem SA, Fouad DA, El-Fatah AA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther 2015;28:194-200.  Back to cited text no. 3
Abd-Elazeim FM, Mohammed GF, Fathy A, Mohamed RW. Evaluation of IL-12 serum level in patients with recalcitrant multiple common warts, treated by intralesional tuberculin antigen. J Dermatolog Treat 2014;25:264-7.  Back to cited text no. 4
Kerure AS, Nath AK, Oudeacoumar P. Intralesional immunotherapy with tuberculin purified protein derivative for verruca: A study from a teaching hospital in South India. Indian J Dermatol Venereol Leprol 2016;Feb 8.doi: 10.4103/0378-6323.175910.[Epub ahead of print]  Back to cited text no. 5
Sterling JC, Gibbs S, Haque Hussain SS, Mohd Mustapa MF, Handfield-Jones SE. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014. Br J Dermatol 2014;171:696-712.  Back to cited text no. 6
Tubersol®: Tuberculin Purified Protein Derivative (Mantoux). Toronto, Ontario, Canada: SanofiPasteur Limited; 2013. Available from: [Last accessed on 2016 Feb 20].  Back to cited text no. 7


Print this article  Email this article


Online since 15th March '04
Published by Wolters Kluwer - Medknow